Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. (Nasdaq: MGNX) is a biopharmaceutical company that publicly describes its focus as discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The MGNX news page on Stock Titan aggregates company-issued updates and third-party coverage so readers can follow how MacroGenics communicates progress across its oncology pipeline, technology platforms and collaborations.
In its press releases, MacroGenics highlights clinical developments for programs such as lorigerlimab, a bispecific PD‑1 × CTLA‑4 DART® molecule, and a portfolio of antibody-drug conjugates including MGC026, MGC028 and MGC030. News items also describe partnered programs like MGD024 with Gilead Sciences, ZYNYZ® (retifanlimab-dlwr) with Incyte and TZIELD® (teplizumab-mzwv) associated with Sanofi, including milestone structures and royalty arrangements disclosed by the company.
MacroGenics regularly issues announcements on quarterly financial results, cash runway expectations, royalty purchase agreements and other financing-related transactions. Additional news covers participation in healthcare and investment conferences, leadership changes such as the appointment of a new President and Chief Executive Officer, and updates on strategic priorities for advancing its antibody-based oncology portfolio and technology platforms.
Investors and observers who follow MGNX news can use this page to review how MacroGenics reports progress in its clinical trials, describes its collaborations and outlines its financial position in official communications. Bookmarking the news feed provides a centralized view of press releases and related information that the company files or references in its SEC disclosures.
MacroGenics (NASDAQ: MGNX) announced the FDA has removed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4.
The company plans to resume enrollment under a revised protocol with additional risk-mitigation measures for hematologic and cardiac toxicities and remains on track to provide a mid-2026 clinical update.
MacroGenics (NASDAQ: MGNX) reported 2025 results, operational updates and 2026 data timelines. Key milestones include initial Phase 1 data for MGC026 in mid-2026, initial Phase 1 data for MGC028 in H2 2026, and an IND submission for MGC030 targeted for 3Q 2026. Cash, cash equivalents and marketable securities were $189.9M as of December 31, 2025, with a stated cash runway into late 2027. 2025 revenue totaled $149.5M, R&D expense was $147.2M, and net loss was $74.6M. The company noted partnership milestone upside with Gilead, Sanofi and Incyte.
MacroGenics (Nasdaq: MGNX) announced participation in multiple investor conferences in March 2026, with CEO Eric Risser delivering hybrid presentations and fireside chats and management holding one-on-one meetings.
Events include TD Cowen (Mar 3, 3:10 pm ET), Leerink Partners (Mar 10, 1:40 pm ET), The Citizens Life Sciences (Mar 11, 10:45 am ET) and Barclays (Mar 12, 10:00 am ET). Webcasts will be available via the company’s Investor Relations "Events & Presentations" page, and archived replays will remain on the site for 30 days.
MacroGenics (NASDAQ: MGNX) said the FDA placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers effective Feb 23, 2026.
No new patients may be enrolled until the hold is lifted; current participants may continue to receive study drug. Four patients experienced serious safety events, including one Grade 5 event. To date, 41 participants have been dosed at 6 mg/kg every three weeks.
MacroGenics (Nasdaq: MGNX) announced that Eric Risser, President and CEO, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 7:55 am ET in Miami, FL.
A live webcast will be available via the company's Investor Relations "Events & Presentations" page and an archived replay will be maintained on the website for 30 days.
MacroGenics (NASDAQ: MGNX) reported third-quarter 2025 results and corporate updates on Nov 12, 2025. The company had $146.4M in cash and marketable securities as of Sept 30, 2025, and expects to receive $75M in partnering payments from Sanofi and Gilead by year-end, extending cash runway into late 2027. Total revenue was $72.8M for Q3 2025 vs. $110.7M in Q3 2024. MacroGenics will stop developing lorigerlimab in second-line mCRPC after interim LORIKEET data but will continue the LINNET Phase 2 study in ovarian/gynecologic cancers. ADC programs MGC026, MGC028 and preclinical MGC030 remain active; an IND for MGC030 is planned for 2026.
MacroGenics (Nasdaq: MGNX) announced that President and CEO Eric Risser will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 4:00 PM ET in New York.
A live webcast will be available via the company's Investor Relations "Events & Presentations" page and an archived replay will be maintained on the website for 30 days.
MacroGenics (NASDAQ:MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. President & CEO Eric Risser will deliver a presentation on Monday, September 8, 2025, at 11:30am ET in New York.
Investors can access the presentation webcast through the company's investor relations website, with a replay available for 30 days following the event.
MacroGenics (NASDAQ: MGNX) reported Q2 2025 financial results and outlined strategic priorities under newly-appointed CEO Eric Risser. The company received a $70 million upfront payment from Sagard Healthcare Partners for ZYNYZ® royalties and reported $176.5 million in cash and equivalents, extending runway through H1 2027.
Q2 2025 highlights include total revenue of $22.2 million (up from $10.8M in Q2 2024) and reduced net loss of $36.3 million (vs $55.7M in Q2 2024). The company is advancing multiple clinical programs, including lorigerlimab's Phase 2 trials and novel ADC pipeline development with MGC026, MGC028, and MGC030.
Strategic priorities include determining lorigerlimab's development path, advancing ADC programs, submitting MGC030 IND, and improving financial position through partnerships and asset monetization.
MacroGenics (NASDAQ: MGNX) has appointed Eric Risser as its new President, Chief Executive Officer, and Board member, effective August 13, 2025. Risser, who has served as Chief Operating Officer since 2022, succeeds Scott Koenig, M.D., Ph.D., who is stepping down after 24 years as CEO.
Risser brings nearly 30 years of biotech and pharmaceutical industry experience and has been with MacroGenics since 2009. Under his leadership in corporate development, the company has generated over $1.6 billion in non-dilutive capital. The outgoing CEO, Dr. Koenig, will continue to serve as Director and advisor, leaving a legacy of three FDA-approved products.